Jinfeng Yang

Jinfeng Yang

Auto-generated profile, based on publicly available information

Jinfeng Yang

Department of Immunology, Guilin Medical University, Guilin 541199, Guangxi, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2022 in Experimental Biology and Medicine
Verified
Journal Article
Closed access
SLShangbo Lei
Shangbo Lei
JJJiamin Jin
Jiamin Jin
XZXiangfeng Zhao
Xiangfeng Zhao
LZLihua Zhou
Lihua Zhou
GQGuangying Qi
Guangying Qi
JYJinfeng Yang
Jinfeng Yang
Interleukin (IL)-33 is a tissue-derived nuclear cytokine belonging to the IL-1 family. Stimulation-2 (ST2) is the only known IL-33 receptor. ST2 signals mostly on immune cells found within tissues, such as regulatory T cells (Treg cells), CD8+ T cells, and natural killer (NK) cells. Therefore, the IL-33/ST2 signaling pathway is important in the immune system. IL-33 deficiency impairs Treg cell function. ST2 signaling is also increased in active Treg cells, providing a new approach for Treg-related immunotherapy. The IL-33/ST2 signaling pathway regulates multiple immune-related cells by activating various intracellular kinases and factors in the tumor microenvironment (TME). Here, we review the latest studies on the role of the IL-33/ST2 signaling pathway in TME and Treg immunotherapy.